China Grants Breakthrough Designation to Orelabrutinib-Mesutoclax Combination
China’s Center for Drug Evaluation granted Breakthrough Therapy Designation to InnoCare’s all-oral orelabrutinib plus mesutoclax combination for marginal zone lymphoma after at least one prior therapy. The designation is based on early Phase I
